Chronic heart failure is a progressive condition where the heart is unable to pump blood efficiently, leading to fatigue, breathlessness, and fluid buildup. Heart failure accounts for around 64 million cases globally, driving the demand for advanced therapies. The growing focus on innovative treatments, such as novel chronic heart failure drug candidates and personalized medicine, is reshaping the market. Factors like an aging population, increased R&D investment, and progress in gene and cell therapies are fueling growth. According to the chronic heart failure pipeline analysis by Expert Market Research, this evolving landscape of treatment options is expected to deliver significant advancements in the coming years, offering hope for better management and quality of life for the affected patients.
Major companies involved in the chronic heart failure pipeline analysis include AstraZeneca, Help Therapeutics, and others.
Leading drugs currently in the pipeline include rhNRG-1, AZD5462, JK07, and others.
Advancements in precision medicine, increased investment in RNA-based therapies, and the development of SGLT2 inhibitors and novel biologics are driving the growth of the chronic heart failure pipeline landscape.
The Chronic Heart Failure Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic heart failure therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic heart failure. The chronic heart failure report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic heart failure pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic heart failure treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic heart failure.
Chronic heart failure is a long-term condition where the heart gradually loses its ability to pump blood efficiently. It occurs due to conditions like coronary artery disease, hypertension, or cardiomyopathy, which weaken or stiffen the heart muscle. Over time, this leads to fluid buildup, fatigue, and shortness of breath, significantly impacting a patient’s quality of life.
Chronic heart failure treatments focus on symptom management and disease progression control. Medications like beta-blockers, ACE inhibitors, and diuretics help improve heart function. Advanced therapies include chronic heart failure drug candidates, implantable devices, and heart transplants for severe cases. Emerging treatments, such as gene and cell therapy, offer hope for improved patient outcomes in the future. For instance, in July 2024, Zydus Lifesciences Ltd. received final United States Food and Drug Administration approval for its Sacubitril and Valsartan tablets, a novel treatment for chronic heart failure in adults. This combination therapy reduces the risk of death and hospitalization, marking a significant advancement in the heart failure pipeline.
Heart failure (HF) is a rapidly growing public health issue affecting approximately 64 million people globally. In the United States, 6.7 million adults are affected, with projections rising to 8.7 million by 2030. In the United Kingdom, 1 million individuals live with HF while in Japan around 370,000 cases are expected by 2025. In India, HF prevalence is 1.2 per 1000 people. The chronic heart failure pipeline is expanding, focusing on innovative therapeutic products to address these escalating epidemiological challenges.
This section of the report covers the analysis of chronic heart failure drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total chronic heart failure clinical trials.
The chronic heart disease pipeline is dominated by Phase II trials, representing approximately 33% of drugs under investigation. The remaining portfolio includes Phase IV at about 26%, Phase III at 21.69%, Phase I at 14.46%, and Early Phase I at 3.61%. This distribution demonstrates a strategic focus on mid-to-late clinical development, reflecting robust progress toward innovative therapies.
The drug molecule categories covered under the chronic heart failure pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapy, RNA-based therapies, and others. The chronic heart failure report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic heart failure.
Small molecule-based ERBB4 agonists are emerging as promising candidates for chronic heart failure treatment. For instance, EF-1, a potent small molecule, effectively induces ERBB4 dimerization, reducing cardiomyocyte cell death, hypertrophy, and fibrosis. This approach offers potential advantages over recombinant proteins, possibly revolutionizing heart failure management through enhanced cardioprotective and anti-fibrotic effects.
The EMR report for the chronic heart failure drug pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic heart failure therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic heart failure clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic heart failure. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic heart failure drug candidates.
rhNRG-1, sponsored by Zensun Sci. & Tech. Co., Ltd., is a recombinant human neuregulin-1β designed to restore cardiomyocyte structure and function in chronic heart failure (CHF). It is a part of a Phase III study, which is evaluating its efficacy in reducing mortality in CHF patients with NT-proBNP levels between 600-1700 pg/mL and NYHA class II-III. rhNRG-1 activates ErbB2/ErbB4 receptors, inhibiting apoptosis and reversing left ventricular remodeling. Preclinical and clinical trials have shown promising results in enhancing heart function and reducing all-cause mortality. The study, enrolling 1,600 participants, is expected to be completed by February 2026.
AZD5462, developed by AstraZeneca, is currently undergoing a Phase II study to evaluate its effects on cardiac function in chronic heart failure (CHF) patients. The study is examining the drug’s efficacy, safety, and pharmacokinetics. AZD5462 is an oral RXFP1 agonist, designed to activate relaxin-2 receptors, improving vascular function and reducing fibrosis. By enhancing cardiac output and lowering vascular resistance, it aims to optimize organ perfusion. AZD5462’s innovative mechanism positions it as a promising chronic heart failure therapeutic product with potential long-term benefits.
JK07, developed by Salubris Biotherapeutics Inc., is currently being evaluated in a Phase II study to assess its safety, tolerability, and efficacy in chronic heart failure patients. This recombinant antibody fusion protein targets the ErbB3 receptor while selectively stimulating ErbB4, enhancing heart regeneration. By improving the therapeutic window of neuregulin-1 (NRG-1), JK07 aims to deliver better clinical outcomes with fewer side effects.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Heart Failure Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic heart failure. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic heart failure collaborations, regulatory environments, and potential growth opportunities.
Congestive Heart Failure (CHF) Epidemiology Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share